The development of tumours under a ketogenic diet in association with the novel tumour marker TKTL1: A case series in general practice

Oncology Letters

Volumn 11, Issue 1, 2016, Pages 584-592

  Jansen, Natalie ^a,b   Walach, Harald ^b  

^a Dr Natalie Jansen Private Practice   (Germany)

^b EUROPEAN UNIVERSITY VIADRINA   (Germany)

Author keywords

Aerobic glycolysis; Cancer; Case series; Diet; Ketogenic diet; TKTL1

Indexed keywords

TRANSKETOLASE LIKE 1; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EATING HABIT; FEMALE; FOLLOW UP; HUMAN; KETOGENIC DIET; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 84948807502     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3923     Document Type: Article

References (60)

1. Sporn MB: The war on cancer. Lancet 347: 1377-1381, 1996.
2. Cancer in Germany 2009/2010, 9th edition. Contributions to the Health Reporting of the Federal Republic. Robert Koch Institut, Berlin, 2013 (In German).
3. Cancer. Fact Sheet 297. World Health Organisation, Geneva, 2014.
4. Paoli A, Rubini A, Volek JS and Grimaldi KA: Beyond weight loss: A review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr 67: 789-796, 2013.
5. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN and Barnard RJ: Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174: 1065-1070, 2005.
6. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW and Santaquilani M; Eurocare Working group: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: Results of the EUROCARE-4 study. Lancet Oncol 8: 773-783, 2007.
7. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, et al; EUROCARE-5 Working Group: Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5 - a population-based study. Lancet Oncol 15: 23-34, 2014.
8. Hölzel D and Engel J: We cannot neglect experiences from clinical practice. The example of metastasising colon tumour shows how clinical registers can help contribute to the evaluation of benefits of medications. Dtsch Arztebl 109: A424-A425, 2012 (In German).
9. Schlesinger-Raab A, Eckel R, Engel J, Sauer H, Löhrs U, Molls M and Hölzel D: Metastasising breast cancer: No prolongation of life since 20 years. Dtsch Arztebl 102: A2706-A2714, 2005 (In German).
10. Gray L, Lee IM, Sesso HD and Batty GD: Association of body mass index in early adulthood and middle age with future site-specific cancer mortality: The Harvard Alumni Health Study. Ann Oncol 23: 754-759, 2012.
11. Ford ES, Bergmann MM, Kröger J, Schienkiewitz A, Weikert C and Boeing H: Healthy living is the best revenge: Findings from the European Prospective Investigation Into Cancer and Nutrition - Potsdam study. Arch Intern Med 169: 1355-1362, 2009.
12. Gonzalez CA and Riboli E: Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer 46: 2555-2562, 2010.
13. Donaldson MS: Nutrition and cancer: A review of the evidence for an anti-cancer diet. Nutrit J 20: 19, 2004.
14. Bao Y, Han J, Hu FB, Giovannucci EL, Stampfer MJ, Willett WC and Fuchs CS: Association of nut consumption with total and cause-specific mortality. N Engl J Med 369: 2001-2011, 2013.
15. Ruskin DN and Masino SA: The nervous system and metabolic dysregulation: Emerging evidence converges on ketogenic diet therapy. Front Neurosci 6: 33, 2012.
16. Fontana L and Klein S: Aging, adiposity, and calorie restriction. JAMA 297: 986-994, 2007.
17. Henderson ST: High carbohydrate diets and Alzheimer's disease. Med Hypotheses 62: 689-700, 2004.
18. Eaton SB and Konner M: Paleolithic nutrition: A consideration of its nature and current implications. N Engl J Med 312: 283-289, 1985.
19. Mellberg C, Sandberg S, Ryberg M, Eriksson M, Brage S, Larsson C, Olsson T and Lindahl B: Long-term effects of a papaeolithic-type diet in obese postmenopausal women: A 2-year randomized trail. Eur J Clin Nutr 68: 350-357, 2014.
20. Warburg O, Posener K and Negelein E: On tumour metabolism. Biochem Z 152: 319-344, 1924 (In German).
21. Zhivotovsky B and Orrenius S: The Warburg Effect returns to the cancer stage. Semin Cancer Biol 19: 1-3, 2009 (Editorial).
22. Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
23. Garber K: Energy boost: The Warburg effect returns in a new theory of cancer. J Natl Cancer Inst 96: 1805-1806, 2004.
24. Romano AH and Conway T: Evolution of carbohydrate metabolic pathways. Res Microbiol 147: 448-455, 1996.
25. Newington JT, Pitts A, Chien A, Arseneault R, Schubert D and Cumming RC: Amyloid β resistance in nerve cell lines is mediated by the Warburg effect. PLoS One 6: e19191, 2011.
26. Gogvadze V, Zhivotovsky B and Orrenius S: The Warburg effect and mitochondrial stability in cancer cells. Mol Aspects Med 31: 60-74, 2010.
27. Weinhouse S: The Warburg hypothesis fifty years later. Z Krebsforsch Klin Onkol 87: 115-126, 1976.
28. Holm E and Kämmerer U: Fat and carbohydrates in diets for tumour patients. Aktuel Ernahrungsmed 36: 286-298, 2011 (In German).
29. Klement RJ and Kämmerer U: Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond) 8: 75, 2011.
30. Otto C, Klingelhöffer C, Biggemann L, Melkus G, Mörchel P, Jürgens C, Gahn S and Kämmerer U: Experimental studies on the metabolism of keton bodies and lactate by tumour cells of the gastrointestinal duct. Aktuel Ernahrungsmed 39: 51-59, 2014 (In German).
31. Vaughn AE and Deshmukh M: Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol 10: 1477-1483, 2008.
32. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, et al: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101: 48-60, 2009.
33. Schmidt M, Pfetzer N, Schwab M, Strauss I and Kämmerer U: Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: A pilot trial. Nutr Metab (Lond) 8: 54, 2011.
34. Kämmerer U: Ketogenic diet for cancer patients. The University Hospital Würzburg, Würzburg, Germany, 2010 (In German).
35. Coy JF and Franz M: The new anti-cancer diet: How you can stop the cancer gene. Volume 1. 1st edition. Gräfe und Unzer, Munich, 2009.
36. Coy JF, Dressler D, Wilde J and Schubert P: Mutations in the transketolase-like gene TKTL1: Clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab 51: 257-273, 2005.
37. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, et al: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94: 578-585, 2006.
38. Sun W, Liu Y, Glazer CA, Shao C, Bhan S, Demokan S, Zhao M, Rudek MA, Ha PK and Califano JA: TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1α stabilization. Clin Cancer Res 16: 857-866, 2010.
39. Schwaab J, Horisberger K, Ströbel P, Bohn B, Gencer D, Kähler G, Kienle P, Post S, Wenz F, Hofmann WK, et al: Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. BMC Cancer 11: 363, 2011.
40. Zhang S, Yang JH, Guo CK and Cai PC: Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 253: 108-114, 2007.
41. Grimm M, Schmitt S, Teriete P, Biegner T, Stenzl A, Hennenlotter J, Muhs HJ, Munz A, Nadtotschi T, König K, et al: A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 13: 569, 2013.
42. Kayser G, Sienel W, Kubitz B, Mattern D, Stickeler E, Passlick B, Werner M and Zur Hausen A: Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology 43: 719-724, 2011.
43. Lange C, Tisch-Rottensteiner J, Böhringer D, Martin G, Schwartzkopff J and Auw-Haedrich C: Enhanced TKTL1 expression in malignant tumors of the ocular adnexa predicts clinical outcome. Ophthalmology 119: 1924-1929, 2012.
44. Feyen O, Coy JF, Prasad V, Schierl R, Saenger J and Baum RP: EDIM-TKTL 1 blood test: A noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol 8: 1349-1359, 2012.
45. Jansen N and Coy JF: Diagnostic use of epitope detection in monocytes blood test for early detection of colon cancer metastasis. Future Oncol 9: 605-609, 2013.
46. Mayer A, Von Wallbrunn A and Vaupel P: Glucose metabolism of malignant cells is not regulated by transketolase-like (TKTL)-1. Int J Oncol 37: 265-271, 2010.
47. Rotmann AR, Hofmann HA and Coy JF: Apo10 - a new biomarker for early detection of disorders of cell proliferation and solid tumours. Abstracts of XX FIGO World Congress of Gynecology and Obstetrics. Int J Gynecol Obstet 119 (Suppl 3): S466, 2012.
48. Fine EJ, Segal-Isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, Bontempo AF, Negassa A and Sparano JA: Targeting insulin inhibition as a metabolic therapy in advanced cancer: A pilot safety and feasibility dietary trial in 10 patients. Nutrition 28: 1028-1035, 2012.
49. Wanka C, Steinbach JP and Rieger J: Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration an dimproving cellular redox homeostasis. J Biol Chem 287: 33436-33446, 2012.
50. Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M and Steinbach JP: ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol 44: 1843-1852, 2014.
51. Guethlin C, Walach H, Naumann J, Bartsch HH and Rostock M: Characteristics of cancer patients using homeopathy compared with those in conventional care: A cross-sectional study. Ann Oncol 21: 1094-1099, 2010.
52. Segar J: Complementary and alternative medicine: Exploring the gap between evidence and usage. Health Lond 16: 366-381, 2012.
53. Walach H: Spiritual and alternative cancer therapies: Strange theories, perhaps wrong, but useful. Breast Care (Basel) 2: 190-192, 2007.
54. Chvetzoff G and Tannock IF: Placebo effects in oncology. J Natl Cancer Inst 95: 19-29, 2003.
55. Walach H (ed): Placebo effects in Complementary and Alternative Medicine: The selfhealing response. In Placebo and Pain: From Bench to Bedside. Elsevier-Academic Press, Amsterdam, pp 189-202, 2013.
56. Walach H: Placebo controls: Historical, methodological and general aspects. Philos Trans R Soc London B Biol Sci 366: 1870-1878, 2011.
57. Fontana L, Partridge L and Longo VD: Extending healthy life span - from yeast to humans. Science 328: 321-326,2010.
58. Mutter J: Healthy instead of chronically ill! The holistic path: prevention instead of treatment. Fit fürs Leben Verlag, Weil der Stadt, 2009 (In German).
59. Ho V, Leung K, Hsu A, Luk B, Lai Jm Shen SY, Minchinton AI, Waterhouse D, Bally MB, Lin W, et al: A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res 71; 4484-4492, 2011.
60. Masko EM, Thomas JA, Antonelli JA, Lloyd JC, Phillips TE, Poulton SH, Dewhirst MW, Pizzo SV, Freedland SJ: Low-carbohydrate diets anmd prostate cancer: How low is ̔low enough̓?: Cancer Prev Res (Phila) 3: 1124-1131, 2010.